Surrogate markers and risk factors for chronic lung allograft dysfunction

Michael E. Bowdish, Selim M. Arcasoy, Jessie S. Wilt, John V. Conte, Robert Duane Davis, Edward R. Garrity, Marshall L. Hertz, Jonathan B Orens, Bruce R. Rosengard, Mark L. Barr

Research output: Contribution to journalArticle

Abstract

Obliterative bronchiolitis (OB) is the histologic correlate of chronic allograft dysfunction in pulmonary transplantation. The histologic diagnosis of OB is challenging, therefore a physiologic definition, bronchiolitis obliterans syndrome (BOS) based on pulmonary function tests has been used as a surrogate marker for OB for the last decade. BOS has proven to be the best available surrogate marker for OB and is predictive of the ultimate endpoints of graft and patient survival. Multiple other clinical markers have been reported and proposed as alternates for or complements to BOS grade, but all need further evaluation and validation in large, prospective clinical trials. Lastly, given the early occurrence and high incidence of chronic allograft dysfunction, the easily measurable endpoint of BOS grade, and our lack of understanding of ways to prevent or alter the course of BOS, lung transplant recipients represent an ideal population for clinical trials targeting prevention and treatment of chronic allograft dysfunction.

Original languageEnglish (US)
Pages (from-to)1171-1178
Number of pages8
JournalAmerican Journal of Transplantation
Volume4
Issue number7
DOIs
StatePublished - Jul 2004

Fingerprint

Bronchiolitis Obliterans
Bronchiolitis
Allografts
Biomarkers
Lung
Clinical Trials
Lung Transplantation
Respiratory Function Tests
Graft Survival
Incidence
Population

Keywords

  • Bronchiolitis obliterans syndrome
  • Graft function
  • Lung transplantation
  • Obliterative bronchiolitis
  • Surrogate markers

ASJC Scopus subject areas

  • Immunology

Cite this

Bowdish, M. E., Arcasoy, S. M., Wilt, J. S., Conte, J. V., Davis, R. D., Garrity, E. R., ... Barr, M. L. (2004). Surrogate markers and risk factors for chronic lung allograft dysfunction. American Journal of Transplantation, 4(7), 1171-1178. https://doi.org/10.1111/j.1600-6143.2004.00483.x

Surrogate markers and risk factors for chronic lung allograft dysfunction. / Bowdish, Michael E.; Arcasoy, Selim M.; Wilt, Jessie S.; Conte, John V.; Davis, Robert Duane; Garrity, Edward R.; Hertz, Marshall L.; Orens, Jonathan B; Rosengard, Bruce R.; Barr, Mark L.

In: American Journal of Transplantation, Vol. 4, No. 7, 07.2004, p. 1171-1178.

Research output: Contribution to journalArticle

Bowdish, ME, Arcasoy, SM, Wilt, JS, Conte, JV, Davis, RD, Garrity, ER, Hertz, ML, Orens, JB, Rosengard, BR & Barr, ML 2004, 'Surrogate markers and risk factors for chronic lung allograft dysfunction', American Journal of Transplantation, vol. 4, no. 7, pp. 1171-1178. https://doi.org/10.1111/j.1600-6143.2004.00483.x
Bowdish, Michael E. ; Arcasoy, Selim M. ; Wilt, Jessie S. ; Conte, John V. ; Davis, Robert Duane ; Garrity, Edward R. ; Hertz, Marshall L. ; Orens, Jonathan B ; Rosengard, Bruce R. ; Barr, Mark L. / Surrogate markers and risk factors for chronic lung allograft dysfunction. In: American Journal of Transplantation. 2004 ; Vol. 4, No. 7. pp. 1171-1178.
@article{7a14d027099941ce9c0a86775f25e958,
title = "Surrogate markers and risk factors for chronic lung allograft dysfunction",
abstract = "Obliterative bronchiolitis (OB) is the histologic correlate of chronic allograft dysfunction in pulmonary transplantation. The histologic diagnosis of OB is challenging, therefore a physiologic definition, bronchiolitis obliterans syndrome (BOS) based on pulmonary function tests has been used as a surrogate marker for OB for the last decade. BOS has proven to be the best available surrogate marker for OB and is predictive of the ultimate endpoints of graft and patient survival. Multiple other clinical markers have been reported and proposed as alternates for or complements to BOS grade, but all need further evaluation and validation in large, prospective clinical trials. Lastly, given the early occurrence and high incidence of chronic allograft dysfunction, the easily measurable endpoint of BOS grade, and our lack of understanding of ways to prevent or alter the course of BOS, lung transplant recipients represent an ideal population for clinical trials targeting prevention and treatment of chronic allograft dysfunction.",
keywords = "Bronchiolitis obliterans syndrome, Graft function, Lung transplantation, Obliterative bronchiolitis, Surrogate markers",
author = "Bowdish, {Michael E.} and Arcasoy, {Selim M.} and Wilt, {Jessie S.} and Conte, {John V.} and Davis, {Robert Duane} and Garrity, {Edward R.} and Hertz, {Marshall L.} and Orens, {Jonathan B} and Rosengard, {Bruce R.} and Barr, {Mark L.}",
year = "2004",
month = "7",
doi = "10.1111/j.1600-6143.2004.00483.x",
language = "English (US)",
volume = "4",
pages = "1171--1178",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Surrogate markers and risk factors for chronic lung allograft dysfunction

AU - Bowdish, Michael E.

AU - Arcasoy, Selim M.

AU - Wilt, Jessie S.

AU - Conte, John V.

AU - Davis, Robert Duane

AU - Garrity, Edward R.

AU - Hertz, Marshall L.

AU - Orens, Jonathan B

AU - Rosengard, Bruce R.

AU - Barr, Mark L.

PY - 2004/7

Y1 - 2004/7

N2 - Obliterative bronchiolitis (OB) is the histologic correlate of chronic allograft dysfunction in pulmonary transplantation. The histologic diagnosis of OB is challenging, therefore a physiologic definition, bronchiolitis obliterans syndrome (BOS) based on pulmonary function tests has been used as a surrogate marker for OB for the last decade. BOS has proven to be the best available surrogate marker for OB and is predictive of the ultimate endpoints of graft and patient survival. Multiple other clinical markers have been reported and proposed as alternates for or complements to BOS grade, but all need further evaluation and validation in large, prospective clinical trials. Lastly, given the early occurrence and high incidence of chronic allograft dysfunction, the easily measurable endpoint of BOS grade, and our lack of understanding of ways to prevent or alter the course of BOS, lung transplant recipients represent an ideal population for clinical trials targeting prevention and treatment of chronic allograft dysfunction.

AB - Obliterative bronchiolitis (OB) is the histologic correlate of chronic allograft dysfunction in pulmonary transplantation. The histologic diagnosis of OB is challenging, therefore a physiologic definition, bronchiolitis obliterans syndrome (BOS) based on pulmonary function tests has been used as a surrogate marker for OB for the last decade. BOS has proven to be the best available surrogate marker for OB and is predictive of the ultimate endpoints of graft and patient survival. Multiple other clinical markers have been reported and proposed as alternates for or complements to BOS grade, but all need further evaluation and validation in large, prospective clinical trials. Lastly, given the early occurrence and high incidence of chronic allograft dysfunction, the easily measurable endpoint of BOS grade, and our lack of understanding of ways to prevent or alter the course of BOS, lung transplant recipients represent an ideal population for clinical trials targeting prevention and treatment of chronic allograft dysfunction.

KW - Bronchiolitis obliterans syndrome

KW - Graft function

KW - Lung transplantation

KW - Obliterative bronchiolitis

KW - Surrogate markers

UR - http://www.scopus.com/inward/record.url?scp=3042826806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042826806&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2004.00483.x

DO - 10.1111/j.1600-6143.2004.00483.x

M3 - Article

VL - 4

SP - 1171

EP - 1178

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 7

ER -